Sign up to save your podcasts
Or
Share ns-MRAs and Biomarkers: The NT-proBNP Connection
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ns-MRAs and Biomarkers: The NT-proBNP Connection
CME credits: 1.25
Valid until: 10-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/ns-mras-and-biomarkers-the-nt-probnp-connection/30064/
Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 1.25
Valid until: 10-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/ns-mras-and-biomarkers-the-nt-probnp-connection/30064/
Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.